Bone marrow megakaryocytes and platelet kinetics in systemic lupus erythematosus. With special reference to corticosteroid and azathioprine therapy.
The megakaryocyte number and mean megakaryocyte area were determined in histological sections of sternal bone marrow from 26 patients with systemic lupus erythematosus (SLE). Also 20 platelet survival studies were carried out in these patients. The results were analyzed with respect to corticosteroid (CS) and CS + azathioprine (AT) therapy. The mean bone marrow megakaryocyte number as highest in untreated SLE patients, slightly lower in patients receiving CSs and lowest in those receiving CSs + AT. The difference was, however, not significant. The mean megakaryocyte areas were smallest in untreated SLE patients, slightly larger in those treated with CSs and significantly (p less than 0.05) larger in patients who received CSs + AT than in untreated patients. Platelet production rate was normal in all 3 groups of SLE patients. The results suggest that CS and AT therapy in SLE intervenes with the bone marrow megakaryopoiesis without affecting the production rate of platelets.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects*; D002452:Cell Count; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008533:Megakaryocytes / Q000187:drug effects*; D008875:Middle Aged
D000305:Adrenal Cortex Hormones; D001379:Azathioprine